The Year's Best Science Fiction: Twenty-Seventh Annual Collection

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, November 7, 2023
VISTA, Research, Insurance, Research and development, The Year's Best Science Fiction: Twenty-Seventh Annual Collection, Northwest Biotherapeutics, ESMO, CD28, Therapy, Society for Immunotherapy of Cancer, VSIG4, Active, Safety, Conference, Translation, MBA, R, Protein, Pharmacokinetics, SITC, Immunotherapy, Sensei, Neoplasm, CD39, Cytokine release syndrome, Annual general meeting, Kinetics, CET, Tumor microenvironment, Society, Cancer, European Society for Medical Oncology, Patient, Administration, MS, Toxicity, Pharmaceutical industry, Vaccine, Cryptocurrency, Antibody, Science, Survival

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2023, and provided recent business updates.

Key Points: 
  • On October 23, 2023, Sensei presented a trial-in-progress poster from the Phase 1/2 clinical trial for SNS-101 at the European Society for Medical Oncology Congress (ESMO) 2023.
  • On November 1, 2023, Sensei announced the announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.
  • General and Administrative (G&A) Expenses: G&A expenses were $3.9 million for the quarter ended September 30, 2023, compared to $4.8 million for the quarter ended September 30, 2022.
  • Net Loss: Net loss was $7.1 million for the quarter ended September 30, 2023, compared to $13.4 million for the quarter ended September 30, 2022.

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Retrieved on: 
Thursday, September 21, 2023
GLP, Translation, CET, Therapy, Poster session, Clinical trial, Cancer, The Year's Best Science Fiction: Twenty-Seventh Annual Collection, Northwest Biotherapeutics, Patient, VISTA, NHP, Kinetics, Phenotype, Tumor microenvironment, Conference, Safety, Medical imaging, Vaccine, Pharmaceutical industry, Science, Survival

BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today will present new preclinical data from SNS-101, a clinical-stage conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Seventh Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held on September 20 – 23, 2023 in Milan, Italy.

Key Points: 
  • “We believe these data further support the potential best-in-class PK and safety profile of SNS-101 and its ability to effectively target VISTA, a promising, but difficult-to-drug immune checkpoint,” said Edward van der Horst, Ph.D., Chief Scientific Officer of Sensei Biotherapeutics.
  • Paired with new mechanistic data showing SNS-101 can shift immunosuppressive macrophages towards an anti-tumor phenotype, we believe SNS-101 could provide a transformative treatment option for patients.
  • The expression of anti-tumor cytokines was correlated with a reduction in tumor size.
  • Sensei is evaluating SNS-101 in a Phase 1/2 clinical trial in patients with advanced solid tumors, and expects to report initial monotherapy pharmacokinetic and safety data by year-end 2023.

The Latino Corporate Directors Association (LCDA) Announces Qualcomm, Comerica Bank, and Granite Construction Inc. to receive Corporate Visionary Award at the Seventh Annual LCDA Board Leaders Convening

Retrieved on: 
Tuesday, October 18, 2022
Amon, Bank of America, TPG, Investor relations, Opportunity, Director, Qualcomm, Chairperson, Bank, Corporation, Program, Blackstone, Multimedia, KPMG, Target, Company, Partnership, Comerica, Goldman Sachs, Learning, Autumn, CEO, Awareness, Morgan Stanley, Intel, The Year's Best Science Fiction: Twenty-Seventh Annual Collection, Convening authority (court-martial), Leadership, Management, Exelon

WASHINGTON, Oct. 18, 2022 /PRNewswire/ -- The Latino Corporate Directors Association (LCDA), the largest national network of Hispanics/Latinos at the pinnacle of corporate leadership and governance, announced its agenda for the Seventh Annual LCDA Board Leaders Convening with this year's theme, Now is Our Time: Capitalizing on the Opportunity, and Fall BoardReady Institute, kicking-off October 25, in New York City, hosted by Morgan Stanley, and presented by KPMG. LCDA was established to raise awareness and drive change around the lack of representation of Hispanics/Latinos on corporate boards.

Key Points: 
  • LCDA was established to raise awareness and drive change around the lack of representation of Hispanics/Latinos on corporate boards.
  • During the Convening, LCDA will present its highest recognition, The Corporate Visionary Award, to three forward-thinking corporations and their leaders for their commitment to advancing Latino representation on their corporate boards.
  • Honorees share the distinction of having two or more US Latinos serve on their boards.
  • Exemplary leaders to be recognized include: Cristiano Amon, President and CEO, Qualcomm Incorporated, Curtis C. Farmer, Chairman, President & CEO, Comerica Incorporated and Comerica Bank; and Michael F. McNally, Board Chair, Granite Construction Incorporated.

Dacha Beer Garden's™ Seventh Annual "Sour Liz" Event Highlights the Best "Pucker Up" Brews to Tickle Tastebuds

Retrieved on: 
Thursday, July 14, 2022
Club, 7th Street, Friends, Probiotic, Digestion, Rare Beer Club, The Year's Best Science Fiction: Twenty-Seventh Annual Collection, Female, Beer, Dacha

WASHINGTON, July 14, 2022 /PRNewswire/ -- It's time to slather on lipstick, pucker up, and take a selfie at Dacha Beer Garden's Shaw location where the Seventh Annual "Sour Liz" Event is in full swing until July 20. Named for the iconic Elizabeth Taylor mural that seems to watch over the beer garden's festivities, "Sour Liz" features more than 14 rare, unusual, and notable sour brews from more than 10 participating breweries and ushers in the latest trend in craft beers, according to Dacha co-founder Dmitri Chekaldin.

Key Points: 
  • "The sours are the fastest-growing beer category at the moment," said Chekaldin.
  • "All of the sour brews are infused with probiotics, which are great for digestion and gut health," he explained.
  • The "Sour Liz" Event runs at Dacha Beer Garden's Shaw location at 1600 7th Street NW location through July 20.
  • Serious beer fans can join the Dacha Beer Club, a free reward-based program.